Esophageal Diseases Highlights From DDW 2022

Sachin Wani, MD


June 20, 2022

Dr Sachin Wani, from the University of Colorado Anschutz Medical Campus, reports on key findings from studies affecting patients with esophageal disease, presented at Digestive Disease Week 2022.

First, Dr Wani discusses a trial that reviewed electronic health records to determine real-world clinical outcomes of patients with Barrett esophagus who underwent endoscopic eradication therapy. He then examines a trial that provided potentially practice-changing results in comparing vonoprazan vs the proton pump inhibitor lansoprazole for treating erosive esophagitis.

Next, Dr Wani looks at a 96-week extension study following the EOS-2 trial which showed that continued use of budesonide orodispersible tablets for patients with eosinophilic esophagitis continues to be highly effective at preventing clinical and endoscopic relapse.

Finally, Dr Wani discusses the predictive value of TissueCypher, a fully automated risk assessment for Barrett esophagus. The study compared the automated results with those of pathologists in determining the risk for malignant progression to high-grade dysplasia and esophageal adenocarcinoma in patients diagnosed with community-based low-grade dysplasia. The results indicate a future approach that may improve risk stratification.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.